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Abstract
Background
Conversion to everolimus is often used in kidney transplantation to overcome calcineurin
inhibitor (CNI) nephrotoxicity but there is conflicting evidence for this approach.
Objectives
To investigate the benefits and harm from randomized clinical trials (RCTs) involving the
conversion from CNI to everolimus after kidney transplantation.
Methods
Databases were searched up to March 2016. Two reviewers independently assessed trials
for eligibility and quality, and extracted data. Results are expressed as risk ratio (RR) or
mean difference (MD) with 95% confidence intervals (CI).
Results
Eleven RCTs, with a total of 1,633 patients, met the final inclusion criteria. Patients con-
verted to everolimus had improved renal function at 1 year posttransplant with an estimated
glomerular filtration rate (eGFR) of 5.36 mL/min per 1.73 m2 greater than patients remaining
on CNI (p = 0.0005) and the longer-term results (> 1 year) of renal function was identical to
that of 1 year. There was not a substantial difference in graft loss, mortality, and the occur-
rence of adverse events (AEs) or serious AEs. However, the risks of acute rejection and trial
termination due to AEs with everolimus are respectively 1.82 and 2.63 times greater than
patients staying on CNI at 1 year posttransplant (p = 0.02, p = 0.03, respectively). Further,
those patients who converted to everolimus had a substantially greater risk of anemia,
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hyperlipidemia, hypercholesterolemia, hypokalemia, proteinuria, stomatitis, mouth ulcera-
tion, and acne.
Conclusions
Conversion from CNI to everolimus after kidney transplantation is associated with improved
renal function in the first 5 years posttransplant but increases the risk of acute rejection at 1
year posttransplant and may not be well endured.
Introduction
Kidney transplantation is the treatment of choice for most patients with end-stage renal dis-
ease. Strategies to increase donor organ availability and to prolong the transplanted kidney’s
survival have become priorities in kidney transplantation. Immunosuppressive therapy is
essential and significant in this respect, nevertheless, but choosing the best suitable immuno-
suppressive therapy is still fairly complex. The calcineurin inhibitors (CNIs) are the principal
components of immunosuppressive therapy after kidney transplantation and have made a
major contribution to current long-term transplant outcomes[1, 2]. Meanwhile, tacrolimus
has been recommended as a first-line agent for kidney transplantation recipients in kidney dis-
ease improving global outcomes (KDIGO) in 2009 [3]. However, CNIs are associated with a
number of potentially serious side effects, including nephrotoxicity, diabetes, hypertension,
and neurotoxicity that contribute to morbidity and mortality after transplantation [4–8].
Upon the fifth year, 90% of grafts revealed evidence of CNI-related lesions, and whereas early
acute nephrotoxicity is typically reversible with CNI minimization; chronic lesions cannot be
altered once initiated [5]. Furthermore, combined therapy with tacrolimus and mycophenolic
acid may be associated with a particularly higher risk of BK infection [9], which is the signifi-
cant and dangerous factor in the failure of the transplanted kidney. Therefore, diminishing or
even eliminating CNI has become the focus of further optimization of immunosuppressive
therapy in renal transplantation.
Everolimus (EVR), a mammalian target of the rapamycin inhibitor (mTORi), works 100
times greater than ciclosporin. It is part of a distinguished group of immunosuppressive drugs
that have a divergent mode of action to that of CNIs even though they bind to the identical
intracellular immunophilin as tacrolimus, namely, FKBP12. The mTORi/FKBP12 complex
binds to and hinders the TORC1 complex, preventing proliferation of numerous cell types,
such as T-lymphocytes, alloprimed B cells, and CD8 TAb-supp cells [10, 11]. The side effect
profile of EVR is different from that of CNI and includes impaired wound healing, mouth
ulcers, stomatitis, arthralgia, hyperlipidemia, and anemia [12–15]. The KDIGO instructions
suggest that EVR should not be initiated prior to surgical wounds healing [3]. However, EVR
may improve renal function and reduce the occurrence of malignancy, which makes it an
attractive alternative to CNIs for maintenance therapy after kidney transplantation [16, 17],
even though it does cause glomerular disease in some patients resulting in marked proteinuria
[18]. A number of randomized controlled trials (RCTs) have examined the potential benefits
of introducing EVR after kidney transplantation using a variety of protocols that differ with
respect to the timing and mode of conversion to EVR, whether CNIs are eliminated or dimin-
ished, and in the level of baseline renal function at the time of EVR introduction. Such studies
have provided conflicting results on the efficacy and side effect profile of EVR.
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Up to now, there is no published work that systematically reviews EVR used as a mainte-
nance therapy in renal transplant recipients. We undertook the meta-analysis of randomized
controlled trials (RCTs) to systematically identify and summarize the current available evi-
dence of the short- and long-term benefits and harm of conversion from CNI to EVR-based
maintenance immunosuppression for kidney transplant recipients.
Materials and Methods
Information Sources and Search Strategies
A systematic literature search was performed using Pubmed/MEDLINE, OVID/EMBASE, and
Cochrane Library covering the period from the inception of the database until March 2016
using a predefined algorithm (S1 Table) without language restrictions. References included in
pertinent systematic reviews were also screened.
Eligibility Criteria
Every RCT examining the conversion from CNI to EVR-based maintenance immunosuppres-
sion in adult isolated kidney transplantation was assessed. Research was judged to be suitable
if they examined sudden or slow conversion to EVR, in the initial or later kidney transplant
recipients, regardless of the time posttransplantation and baseline renal function. Trials that
were deemed suitable included those in which the intervention (conversion to EVR) and refer-
ence (CNI continuation) groups were administered more maintenance immunosuppression
comprising antimetabolites (mycophenolate or azathioprine) and steroids. Observational and
uncontrolled studies, those examining children, those in which the participants obtained other
solid organs plus a renal transplantation, and animal trials were eliminated.
Data Extraction
Data removal was done separately by 2 investigators (Jinyu Liu and Ruxu You) and discrepan-
cies were resolved by a third investigator (Juan Li). We documented data on trial characteris-
tics and demographics, such as authors’ names, year published, journal’s name, sample size
per-arm, population characteristics, indications, CNI dose, EVR characteristics (bolus and
maintenance dose, mode of administration, timing of intervention, sudden stopping or taper-
ing of prior immunosuppression) and length of the trial. The main meta-analysis result was
renal function (estimated Glomerular Filtration Rate, eGFR) and secondary results were acute
rejection, graft loss, patient survival and AEs. All of the results were investigated 1 year post-
transplantation; long-term results, if available, were also investigated.
Assessment of Methodological Quality
The methodological quality of the included trials and the risk of bias were evaluated with ele-
ments from the Cochrane Collaboration’s tool for determining the risk of bias [19, 20]. The
domains implemented in the current systematic review concerned randomization and alloca-
tion concealment (selection bias), blinding (performance and detection bias), loss to follow-
up, and keeping to the intention-to-treat principle (attrition bias), selective reporting (report-
ing bias), and other biases. We decided to put forth the meta-analysis of every one of the stud-
ies while offering a synopsis of the risk of bias across trials.
Data Synthesis and Statistical Analysis
For every study we recovered, we computed the crude risk ratio (RR) estimates and corre-
sponding 95% confidence intervals (CI) for the evaluated binary results (acute rejection, graft
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loss, patient survival, and AEs), and the mean difference (MD) and corresponding standard
deviation (SD) for the evaluated continuous outcomes (GFR). The existence of statistically sig-
nificant heterogeneity was evaluated using the Cochran Q test and the degree of the observed
heterogeneity was evaluated by the I2 (ranging from 0% to 100%). A Cochran’s Q p< 0.10 was
considered to show significant heterogeneity, and analysis was undertaken using the random
effects model. Otherwise, the fixed effects model was used. Summary effect estimates for renal
function, acute rejection, graft loss, and patient survival were set on intention-to-treat (ITT)
groups as identified in the study publications; further, all qualified trials documented AEs in
the safety population and, therefore, summary effect sizes for AEs were approximated using
safety populations as stated in the study publications.
Pre-determined subgroup analyses were done to investigate origins of heterogeneity; trials
were stratified by time of conversion to EVR (early versus late conversion, defined as 3
months after transplantation) or by the duration to follow up. Sensitivity analyses were done
based on to the protocol examining GFR or acute rejection. To additionally determine moder-
ators of the noted effect estimates, a meta-regression analysis was performed to account for
baseline renal function. Publication bias was investigated using funnel plots. Where informa-
tion was missing we contacted the researchers to seek the pertinent information. Analyses
were done in RevMan 5.3 (Cochrane Collaboration, 2014) and STATA 10 (STATA Corp., Col-
lege Station, TX). All p values were 2-tailed. The study is documented based on the favored
reporting items for systematic reviews and meta-analyses checklist [21].
Results
Description of Studies
We identified 3,129 possibly relevant references (PubMed, 673; Ovid, 1801; Cochrane Library,
643; and other sources, 12). After examining the titles and abstracts and eliminating identical
publications, 67 possibly qualified articles were determined. Fifteen reports [22–36] of 11 trials,
including a total of 1,633 randomized patients, were chosen for inclusion in the meta-analysis
(Fig 1). One of these trials was available in abstract form only by Wolfgang et al 2012 [31].
Nine trials compared EVR to cyclosporine, and 2 trials compared EVR to CNI (cyclosporine
or tacrolimus).
All of the incorporated studies were designed to determine the safety and efficacy of conver-
sion from CNI to EVR in adult kidney transplant patients. Design characteristics, immunosup-
pression regimens, and reported results for every study are summarized in Table 1. The
median sample size was 96 participants (interquartile range, 13–337), and the median treat-
ment duration was 19.5 months (with a minimum of 6 months and a maximum of 60 months).
All of the trials stated renal function, acute rejection, graft loss, patient survival, and AEs. GFR
was estimated by Nankivell formula in 5 trails [24–27, 29–33], modification of diet in renal dis-
ease (MDRD) formula in 3 trails [22, 34, 35], and was unclear in 3 studies [23, 28, 36]. Early
conversion to EVR (defined as3 months after transplantation) was evaluated in 5 studies
[22, 23, 25, 28, 30, 31], whereas 6 studies evaluated the late conversion to EVR [24, 26, 27, 31,
32–36]. There was a difference in baseline renal function, both within and between the trials,
but most of the patients had mild or moderate renal dysfunction at the time of randomization.
Risk of Bias in Included Studies
The Cochrane Collaboration tool was implemented to evaluate the risk of bias (Fig 2 and S1
Fig). All trials were randomized, but 3 trials gave no indication of the allocation method used.
Ten trials were open-label and only 1 trial reported blinding investigators [35]. Attrition was
Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation
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adequately reported in 10 trials and was generally low (< 20%). Intention-to-treat analysis was
confirmed for 6 trials and was unclear for the remaining 5 trials.
Assessed Outcomes and Evidence Synthesis
Renal function. Renal function was reported at 1, 2, 3, and 5 years after transplantation
by 8, 5, 3 and 2 included studies, respectively. In the ITT analysis, patients converted to EVR
had significantly better renal function at 1, 2, 3, and 5 years after transplantation compared to
patients remaining on CNI [(MD, 5.36; 95% CI, 2.32–8.39; I2, 51%), (MD, 6.91; 95% CI, 3.04–
10.79; I2, 32%), (MD, 6.65; 95% CI, 1.61–11.70; I2, 53%), and (MD, 6.50; 95% CI, 2.38–10.63;
I2, 0%); Fig 3A]. When studies were stratified according to the time of conversion to EVR
(early versus late conversion, defined as 3 months after transplantation), there was a statisti-
cally significant trend toward a more favorable GFR difference between EVR and CNI groups
in the late conversion trials (MD, 9.42; 95% CI, 6.13–12.70; I2, 0%) compared to the early con-
version trials (MD, 3.65; 95% CI, 0.70–6.60; I2, 27%), with reduction in heterogeneity (Fig 3B).
Fig 1. Flow chart of included studies in the meta-analysis.
doi:10.1371/journal.pone.0170246.g001
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Table 1. Characteristics of included studies.
Study ID Study
design
Time to
conversion
since
transplant
Immunosuppressive dosing regime Outcomes reported follow
up (m)Method of
switching
Pre-
conversion
Intervention Comparator CNI in the
interventionarm
after switching
GFR Graft
loss
Mortality Acute
rejection
AEs
Wolfgang
2012 [31]
a
prospective
open-label
multicenter
RCT
(N = 337)
3 m Unclear CsA,
EC-MPS,
steroids
EVR: Target
level (5–
10ng/ml),
EC-MPS,
steroids
(N = 171)
CsA,
EC-MPS,
steroids
(N = 166)
Unclear p p p p p 12
Thibault
2016 [22]
a
prospective
multicenter
open-label
RCT (N = 13)
within 24 h No
conversion
No EVR: Bolus
(6mg/d),
Target level
(6–10ng/ml),
EC-MPS,
steroids
(N = 7)
CsA,
EC-MPS,
steroids
(N = 6)
None p p p p p 6
Seckinger
2008 [35]
a
prospective
single-center
RCT (N = 39)
6 m Tapered CsA, MPA,
steroids
EVR: Target
level (6–
10ng/ml),
MPA,
steroids
(N = 20)
CsA, MPA,
steroids
(N = 19)
CsA p p p p p 15
Budde
2011 [33]
a
prospective
multicentrer
parallel-
group RCT
(N = 300)
4.5 m Tapered CsA,
EC-MP,
steroids
EVR: Bolus
(1.5mg/d),
Target level
(6–10ng/ml),
EC-MPS,
steroids
(N = 154)
CsA,
EC-MPS,
steroids
(N = 146)
CsA p p p p p 12
Mjo¨rnstedt
2012 [30]
an open-
label
multicenter
RCT
(N = 202)
7 w Abrupt CsA,
EC-MP,
steroids
EVR: Bolus
(3mg/d),
Target level
(6–10ng/ml),
EC-MPS,
steroids
(N = 102)
CsA,
EC-MPS,
steroids
(N = 100)
None p p p p p 12
Rostaling
2015 [23]
a
prospective
open-label
multicenter
RCT
(N = 194)
3 m Tapered CsA,
EC-MPS,
steroids
EVR: Bolus
(3mg/d),
Target level
(6–10ng/ml),
EC-MPS,
steroids
(N = 96)
CsA,
EC-MPS,
steroids
(N = 98)
CsA p p p p p 12
Chadban
2014 [28]
a
prospective
multinational
open-label
RCT (N = 96)
2 w Tapered CsA, MPA,
steroids
EVR: Target
level (8–
12ng/ml),
steroids
(N = 48)
CsA, MPA,
steroids
(N = 47)
CsA p p p p p 12
Budde
2015 [27]
an open-
label
prospective
parallel-
group RCT
(N = 93)
> 6m Tapered CsA or
TaC,
EC-MPS,
steroids
EVR: Bolus
(1.5mg/d),
Target level
(6–10ng/ml),
EC-MPS,
steroids
(N = 46)
CsA or TaC,
EC-MPS,
steroids
(N = 47)
CsA or TaC p p p p p 12
Bemelman
2009 [34]
a
prospective
multicenter
open-label
RCT (N = 77)
6 m Tapered CsA, MPS,
steroids
EVR: Target
AUC12(150
mgh/L),
EC-MPS,
steroids
(N = 38)
CsA, MPS,
steroids
(N = 39)
CsA p p p p p 24
(Continued)
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To additionally confront heterogeneity for renal function at 1 year after conversion to EVR,
sensitivity analyses were done using the estimating procedures of GFR. We performed sensi-
tivity analysis excluding 2 trials [22, 35] that reported GFR estimates based on MDRD and a
similar effect to the original meta analysis was observed (MD, 5.18; 95% CI, 2.07–8.30; I2,
56%). We performed additional sensitivity analysis excluding 2 trials [19, 24] that did not spec-
ify just which methods used to estimate GFR and a similar effect to the original meta analysis
was observed (MD, 6.30; 95% CI, 3.06–9.53; I2, 42%). Further, meta-regression analyses taking
into consideration the baseline GFR calculations revealed that the baseline renal function did
not have a substantial impact on the difference in renal function between EVR and CNI groups
1 year posttransplantation.
Table 1. (Continued)
Study ID Study
design
Time to
conversion
since
transplant
Immunosuppressive dosing regime Outcomes reported follow
up (m)Method of
switching
Pre-
conversion
Intervention Comparator CNI in the
interventionarm
after switching
GFR Graft
loss
Mortality Acute
rejection
AEs
Holdaas
2011 [32]
an open-
label
multicenter
RCT
(N = 250)
6 m Tapered CsA or
TaC, MPA,
Aza,
steroids
EVR: Target
level (6–
10ng/mL),
MPA, Aza,
steroids
(N = 127)
CsA or TaC,
MPA, Aza,
steroids
(N = 123)
CsA or TaC p p p p p 24
Kihm 2009
[36]
a
prospective
single-center
RCT (N = 32)
12 m Tapered CsA, MPA,
steroids
EVR: Bolus
(3mg/d),
Target level
(6–10ng/ml),
MPA,
steroids
(N = 17)
CsA, MPA,
steroids
(N = 15)
CsA p p p p p 24
Budde
2012 [29]
a
prospective
multicentrer
parallel-
group RCT
(N = 300)
4.5 m Tapered CsA,
EC-MPS,
steroids
EVR: Bolus
(1.5mg/d),
Target level
(6–10ng/ml),
EC-MPS,
steroids
(N = 154)
CsA,
EC-MPS,
steroids
(N = 146)
CsA p p p p p 36
Mjo¨rnstedt
2015 [25]
an open-
label
multicenter
RCT
(N = 202)
7 w Abrupt CsA,
EC-MPS,
steroids
EVR:Bolus
(3mg/d),
Target level
(6–10ng/ml),
EC-MP,
steroids
(N = 102)
CsA,
EC-MPS,
steroids
(N = 100)
None p p p p p 36
Budde
(ZEUS)
2015 [24]
a
prospective
multicentrer
parallel-
group RCT
(N = 300)
4.5 m Tapered CsA,
EC-MPS,
steroids
EVR: Bolus
(1.5mg/d),
Target level
(6–10ng/ml),
EC-MPS,
steroids
(N = 154)
CsAEC-MPS
steroids
(N = 146)
CsA p p p p p 60
Budde
(APOLLO)
2015 [26]
an open-
label
prospective
parallel-
group RCT
(N = 93)
>6 m Tapered CsA or
TaC,
EC-MPS,
steroids
EVR: Bolus
(1.5mg/d),
Target level
(6–10ng/ml),
EC-MPS,
steroids
(N = 46)
CsA or TaC,
EC-MPS,
steroids
(N = 47)
CsA or TaC p p p p p 60
CsA, cyclosporine A; EVR, everolimus; TaC, tacrolimus; Aza, azathioprine; MPA, mycophenolic acid; CNI,calcineurin inhibitor; EC-MPS, enteric-coated
mycophenolate sodium; GFR, glomerular filtration rate; AEs, adverse effects; RCT, randomized controlled trail; h, hour; m, month; w, week.
doi:10.1371/journal.pone.0170246.t001
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Acute rejection. Every one of the included studies added to the meta-analysis examining
the link between conversion from CNI to EVR and acute renal allograft rejection. Every one of
the trials implemented the description of biopsy-proven acute rejection (BPAR), excluding the
trial by Seckinger et al [35]. In contrast to CNI maintenance, conversion to EVR was linked
with a greater risk of documented acute rejection 1 year posttransplantation (RR, 1.82; 95%
CI, 1.11–2.99; I2, 43%; Fig 4A). Analysis based on a definition of BPAR showed similar find-
ings (RR, 1.91; 95% CI, 1.12–3.25; I2, 50% for patients converted to EVR). However, patients
converted to EVR had a similar risk of acute rejection compared with the patients remaining
on CNI up to 2, 3, and 5 years after transplantation [(RR, 1.55; 95% CI, 0.35–6.82; I2, 14%),
(RR, 1.62; 95% CI, 0.67–3.92; I2, 71%), and (RR, 1.85; 95% CI, 0.94–3.65; I2, 0%); Fig 4A].
Moreover, we performed subgroup analysis between early conversion (between 0~3 months)
and late conversion (> 3 months), and the subgroup analysis showed that early conversion to
EVR compared to CNI maintenance was associated with a significantly higher risk of acute
rejection up to 1 year after transplantation. In contrast, late conversion to EVR compared to
CNI maintenance had a higher risk of acute rejection than CNI maintenance and it did not
reach statistical significance (Fig 4B). In total, subgroup analyses did not show statistical het-
erogeneity among the 2 subgroups (I2 = 0%, p = 0.59).
Renal allograft loss and mortality. There were 3 trials [23, 28, 31] that added to the
meta-analysis examining the link between conversion from CNI to EVR and renal allograft
loss while in the 5 other trials [22, 27, 30, 33, 35], no renal allografts were lost up to the first
year posttransplantation. Patients converted to EVR had a similar risk of graft loss compared
with the patients remaining on CNI (RR, 1.43; 95% CI, 0.44–4.68; I2, 37%; Fig 5). Overall, 6
(0.93%) patients in the EVR group and 4 (0.93%) patients in the CNI group lost their graft
within the first year after transplantation. There was no significant difference for long-term
graft loss as well.
Mortality up to 1 year posttransplantation was reported in 8 studies. Altogether, 4 (0.62%)
patients in the EVR group and 6 (0.95%) patients in the CNI group died within the first year
after transplantation. There were no distinctions in mortality among patients who converted
Fig 2. Quality of included studies in the meta-analysis.
doi:10.1371/journal.pone.0170246.g002
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Fig 3. A. Everolimus versus calcineurin inhibitor; mean GFR up to 1–5 years after transplantation stratified by study duration. B.
Everolimus versus calcineurin inhibitor; mean GFR up to 1 year after transplantation stratified by time to conversion.
doi:10.1371/journal.pone.0170246.g003
Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation
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Fig 4. A. Everolimus versus calcineurin inhibitor; any rejection up to 5 years after transplantation stratified by study duration. B. Everolimus versus
calcineurin inhibitor; any rejection up to 1 year after transplantation stratified by time to conversion.
doi:10.1371/journal.pone.0170246.g004
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to EVR and those who continued on CNI (RR, 0.70; 95% CI, 0.22–2.18; I2, 0%; Fig 6A). Risk
ratios (RRs) and heterogeneity were alike when studies were stratified based on the time of
conversion to EVR (Fig 6B). There was no significant difference for long-term mortality as
well.
Treatment failure. Five studies [27, 28, 30, 31, 33] reported treatment failure 1 year post-
transplantation. Overall, 64 (18.19%) patients in the EVR group and 29 (8.43%) patients in the
CNI group failed within the first year after transplantation. There were no differences in
Fig 5. Everolimus versus calcineurin inhibitor; graft loss within 5 years after transplantation stratified by study duration.
doi:10.1371/journal.pone.0170246.g005
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treatment failure between patients converted to EVR and those remaining on CNI (RR, 1.74;
95% CI, 0.79–3.86; I2, 67%).
Adverse events. Every one of the trials involved in the meta-analysis documented adverse
events (AEs), although there were differences between studies in the nature and incidence of
the reported adverse events. The main AEs involved in infection, blood and lymphatic system
disorders, gastrointestinal disorders, metabolism and nutrition disorders, and the body as a
whole-general disorders. Overall, 427 (94.05%) patients in the EVR group and 403 (90.77%)
patients in the CNI group suffered 1 or more AEs within the first year after transplantation.
There were no differences in the incidence of AEs or serious AEs between patients converted
to EVR and those remaining on CNI [(RR, 1.04; 95% CI, 1.00–1.08; I2, 0%), and (RR, 1.07;
95% CI, 0.96–1.21; I2, 18%); Fig 7A and 7B]. However, the risk of study discontinuation due to
AEs up to 1 year after transplantation was greater in patients converted to EVR than in patients
remaining on CNI (RR, 2.63; 95% CI, 1.13–6.15; I2, 69%).
Fig 6. A. Everolimus versus calcineurin inhibitor; mortality up to 1–5 years after transplantation stratified by study
duration. B. Everolimus versus calcineurin inhibitor; mortality up to 1 year after transplantation stratified by time to
conversion.
doi:10.1371/journal.pone.0170246.g006
Fig 7. A. Everolimus versus calcineurin inhibitor; any adverse events up to 1 year after transplantation; B. Everolimus versus calcineurin inhibitor; any
serious adverse events up to 1 year after transplantation.
doi:10.1371/journal.pone.0170246.g007
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Reported adverse events, along with RR estimates and 95% CI up to 1 year after transplanta-
tion, are summarized in Fig 8 and S2 Table. Compared with patients on CNI continuation,
those converted to EVR had a substantially higher risk of anemia, hyperlipidemia, hypercho-
lesterolemia, hypokalemia, proteinuria, stomatitis, mouth ulceration, acne and a nonstatisti-
cally significant trend toward a higher risk of thrombocytopenia. Nevertheless, patients
converted to EVR had a lower risk of cytomegalovirus, BK virus, and urinary tract infection,
diabetes mellitus, hypertriglyceridemia, malignancy, and cough; however, it did not reach sta-
tistical significance (Table 2).
As for long-term safety, we did not perform meta-analysis because there were too few trials
within the same duration. The occurrence of AEs and serious AEs was similar in the EVR
group versus the CNI group. The most recurrent AEs (> 10%) were anemia, diarrhea, periph-
eral edema, proteinuria, mouth ulceration, pyrexia, urinary tract infection, upper respiratory
Fig 8. Pooled risk ratio estimates and 95% confidence intervals for adverse events up to 1 year after transplantation.
doi:10.1371/journal.pone.0170246.g008
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tract infection, increased serum creatinine, cough, rash, and acne; the first 5 were substantially
elevated in the EVR group than the CNI group (p< 0.05). In addition, leukocyte and platelet
counts were decreased and liver enzymes (aspartate aminotransferase and alanine aminotrans-
ferase) and lipids (total cholesterol and triglycerides) were substantially elevated in the EVR
group versus the CNI group (p< 0.05). No AEs were documented less commonly in the EVR
group with a statistical difference.
Discussion
The findings from this meta-analysis establish that conversion from CNI to EVR-based main-
tenance immunosuppression after kidney transplantation is associated with an increased
eGFR (about 10%, p< 0.01) up to 5 years after transplantation. There were no substantial dif-
ferences in efficacy results between the 2 groups except that recipients who converted to EVR
had a higher risk of acute graft rejection up to 1 year after transplantation. In terms of safety
and tolerability, results were subordinate in the EVR group in contrast to the CNI group.
In renal transplantation, chronic allograft nephropathy (CAN) continues to be the primary
reason for graft loss[37, 38]. CAN is characterized by a gradual decline of renal function with
interstitial fibrosis and tubular atrophy, which causes proteinuria, high blood pressure, and a
gradual escalation in serum creatinine. GFR is the most commonly utilized marker for the
decline in renal function. Further, scientists have proposed that early low-grade proteinuria
could offer a different marker to GFR for future risk [39–41]. Two previous meta-analysis [14,
42] evaluated mTORi for primary immunosuppression of kidney transplant recipients and
concluded that mTORi showed significantly lower serum creatinine and more improved
eGFR than those treated with a CNI. In the present meta-analysis, every one of the RCTs were
available for analysis on renal function with GFR as the main endpoint. Our analysis con-
ducted that eGFR was significantly elevated in the EVR group versus the CNI controls: a mean
difference of 5.36mL/min per 1.73m2 (p = 0.0005) at 1 year and 6.50 mL/min per 1.73m2
(p = 0.002) 5 years after transplantation. Given the observed marked heterogeneity (I2, 51%)
for trials reporting on the effect of EVR conversion on renal function at 1 year after
Table 2. Incidence of the most common adverse events up to 1 year after transplant.
Adverse events Incidence of adverse events (%) p-Value
Everolimus CNI
anemia 13.92 8.52 0.004
hyperlipidemia 10.15 5.23 0.006
hypercholesterolaemia 11.11 5.59 0.01
hypokalaemia 6.25 1.63 0.02
proteinuria 8.55 3.53 0.007
stomatitis 18.04 1.94 <0.00001
mouth ulceration 15.38 0.75 <0.00001
acne 10.25 1.63 0.0005
thrombocytopenia 5.12 2.23 0.29
cytomegalovirus 8.90 11.59 0.11
BK virus 2.85 4.88 0.14
urinary tract infection 21.48 25.61 0.27
diabetes mellitus 4.92 8.29 0.16
hypertriglyceridaemia 2.16 2.51 0.77
malignancy 5.62 7.08 0.51
cough 6.97 7.35 0.90
doi:10.1371/journal.pone.0170246.t002
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transplantation, caution is required with respect to the magnitude of the overall estimate for
this outcome. Subgroup and sensitivity analyses reinforced the overall conclusion that conver-
sion to EVR was associated with improved eGFR and eliminated heterogeneity as well. Never-
theless, those patients who converted to EVR had a substantially greater risk of proteinuria
(8.55% vs 3.53%, p = 0.007) at 1 year after the transplant and 2 patients developed proteinuria
>1,000 mg/day post-conversion to everolimus. Offset against the insistent eGFR advantage of
conversion to everolimus, this risk would seem to be allowable but because patients with ele-
vated urine protein (e.g.> 150 or> 500 g/day) at the time of conversion seem to be more sus-
ceptible to gradual proteinuria after conversion to EVR [43], the transition should be avoided
or done with care.
It has been reported that conversion from CNI to mTORi increases the risk of acute rejec-
tion [16, 22]. The present meta-analysis showed that conversion to EVR is associated with a
higher risk of acute rejection at 1 year after transplantation. However, there was a similar risk
of long-term acute rejection (> 1 year). Since the risk for acute rejection is highest in the first 3
months after transplantation [3], we did subgroup analysis between early conversion (between
0 and 3 months) and late conversion (> 3 months). The subgroup analysis showed that early
conversion to EVR compared to CNI maintenance was associated with a significantly higher
risk of acute rejection up to 1 year after transplantation; in contrast, although late conversion
had a higher risk of acute rejection, it did not reach statistical significance. The meta-analysis
showed that late versus early conversion to EVR was associated with a trend toward better
renal function and a lower risk of acute rejection at 1 year. According to the evidence, late
transition may be the better advice. In the 8 trials, only 1 trial abruptly discontinued CNI, so
the present analysis did not show a difference in acute rejection between the trials evaluating
abrupt and tapered discontinuation of CNI. However, experience in liver transplantation sug-
gests that tapered discontinuation is preferable, especially when EVR conversion is introduced
within the first few months of transplantation [44].
Mammalian target of rapamycin inhibitors are associated with a number of well-described
side effects [4, 13, 18] that may limit the ability of patients to tolerate them. Our analysis con-
firmed this, indicating that the risk of study discontinuation due to AEs after EVR conversion
was 2.63 times that of the patients maintained on CNIs. Overall, there was a substantial risk of
adverse events after conversion to EVR, and this represents a significant barrier for its utility
in preserving renal function after kidney transplantation. It was reported that EVR may lead an
increased risk of bone marrow suppression [42]. Our analysis showed that conversion to EVR
had a significantly higher risk of anemia, and a higher risk of thrombocytopenia, and leucopenia
with no significant difference. Therefore, the real harm of EVR-induced thrombocytopenia and
leukopenia is unclear from these trials. In addition, our analyses showed that conversion to
EVR is associated with an increased risk of hyperlipidemia and hypercholesterolemia, although
the requirements for a new statin therapy was not different to patients maintained on CNI.
Conversion to EVR significantly increased the risk of stomatitis by 9.30 times (p< 0.00001)
and mouth ulceration by 20.51 times (p< 0.00001) than CNI, but the rate of infection was simi-
lar to that of patients on CNI maintenance. A significant drawback of treatment with mTORi is
the development of proteinuria which may reach the nephrotic range, especially after exposure
to high everolimus concentrations [45]; our analysis confirmed the association between EVR
and proteinuria, although the reported proteinuria levels were usually mild or less often moder-
ate. We were unable to confirm any benefit in reduced malignancy in these 11 randomized tri-
als, although this has been suggested by other data [46, 47]. The main limitation of this review is
that of the contributory trials. Additionally, where graft-focused outcomes were well reported,
many of the potentially informative patient-focused adverse outcomes were not reported, not
defined, or inconsistently reported.
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A longitudinal cohort study included 9,353 kidney transplant recipients showed that
mTORi use was associated with a higher risk of all-cause mortality but not allograft loss [48].
The majority of RCTs included in our meta-analysis were not powered to detect a difference
in graft or patient survivals, and the true effect of EVR conversion on graft and patient out-
comes is still to some extent uncertain. This is especially the case for long-term outcomes,
although there are 6 trials included in the meta-analysis reported outcomes beyond 1 year,
they scatter in different time periods. As to long-term safety, there are too few studies to per-
form a meta-analysis. This review focuses on the requirement for follow-up of clinical studies
in transplantation to go well beyond the immediate term to 5 years and beyond. This has been
shown in renal transplantation in which a coordinated effort between the researchers and a
registry of long-term patient follow-up of up to 15 years posttransplantation [49].
There are further possible restrictions in the current meta-analysis. First, we did not incor-
porate any unpublished evidence, so there may be publication bias in the meta-analysis. Sec-
ond, even though randomized evidence is safeguarded from selection bias, performance and
detection biases could be possible confounders. An approach toward addressing this would be
to exempt open-label trials. Ultimately, the majority of the incorporated trials were, by neces-
sity, open-label trials, and so trial exclusion was not a viable choice. Lastly, a group of study
parameters could possibly impede our study outcomes. The variation in baseline renal func-
tion between studies, and the unmistakable patient characteristics inside separate studies may
have added to the noted heterogeneity.
Conclusion
The currently available randomized evidence indicates that conversion from CNI to EVR after
kidney transplantation is associated with short and long-term improvements in GFR in a num-
ber of studies, but these findings must be balanced against the greater rates of proteinuria, dis-
continuation due to AEs, and higher incidences of acute rejection up to 1 year posttransplant
with the use of EVR as compared with CNI. Moreover, late conversion to EVR might be asso-
ciated with a trend toward better renal function and a lower risk of acute rejection up to 1 year
posttransplantion than early conversion. Additionally, in deciding the optimal immunosup-
pression strategy for their patients, clinicians should be alert to the increased risk of bone mar-
row suppression, dyslipidemia, mouth ulceration, and stomatitis after conversion to EVR
which, however, has no effect on graft and patient survival.
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